Compare AGRO & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGRO | KARD |
|---|---|---|
| Founded | 2002 | 2023 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 2026 |
| Metric | AGRO | KARD |
|---|---|---|
| Price | $9.01 | $15.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $13.44 | ★ $41.13 |
| AVG Volume (30 Days) | ★ 524.0K | 512.9K |
| Earning Date | 11-11-2026 | 11-22-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.28 | N/A |
| Revenue Next Year | $5.47 | $50.00 |
| P/E Ratio | $37.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.89 | $12.23 |
| 52 Week High | $15.89 | $27.00 |
| Indicator | AGRO | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 57.14 |
| Support Level | $8.92 | $12.28 |
| Resistance Level | $10.09 | $15.93 |
| Average True Range (ATR) | 0.31 | 1.14 |
| MACD | -0.05 | 0.35 |
| Stochastic Oscillator | 7.69 | 78.38 |
Adecoagro SA is a Luxembourg-based agricultural company. It is involved in a wide range of businesses, including farming crops and other agricultural products, dairy operations sugar, ethanol, energy production, and land transformation. The group operates in two lines of business, namely, Farming and Sugar, Ethanol and Energy. The Farming is further comprised of three reportable segments: Crops, Rice and Dairy. Sugar, Ethanol and Energy Segment, consists of cultivating sugarcane, which is processed in owned sugar mills, transformed into ethanol, sugar and electricity, in addition to biomethane and then marketed.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.